Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555525 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study on the Use of Seysara for Rosacea
A Phase 4 study of Acne Rosacea, sponsored by Derm Research, P.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04555525 is a Phase 4 study of Acne Rosacea that has completed, run by Derm Research, P. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04555525, a Phase 4 study of Acne Rosacea, has completed, sponsored by Derm Research, P.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)
Conditions Studied
Interventions
- DRUG sarecycline
- DIETARY_SUPPLEMENT Centrum Adult Multivitamin
Study Locations (1)
Kentucky
- Skin Sciences, PLLC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04555525
The ClinicalTrials.gov registry entry for NCT04555525 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Derm Research, P, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Rosacea appearing as the primary indexed condition, and to 2 interventions - of which sarecycline is the first listed.
NCT04555525 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT04555525 about?
NCT04555525 is a clinical study titled "A Pilot Study on the Use of Seysara for Rosacea". This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screen...
What is the current status of trial NCT04555525?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2019-04-15. Estimated completion is 2020-10-01.
What conditions does trial NCT04555525 study?
This clinical trial studies the following conditions: Acne Rosacea.
What interventions are being tested in trial NCT04555525?
The interventions under investigation include: sarecycline (DRUG), Centrum Adult Multivitamin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04555525?
This trial is sponsored by Derm Research, P, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04555525 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.